The challenge of developing human 3D organoids into medicines

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Vives, Joaquim
• dc.contributor.author Batlle Morera, Laura
• dc.date.accessioned 2020-05-12T07:22:41Z
• dc.date.available 2020-05-12T07:22:41Z
• dc.date.issued 2020
• dc.description.abstract The capacity of organoids to generate complex 3D structures resembling organs is revolutionizing the fields of developmental and stem cell biology. We are currently establishing the foundations for translational applications of organoids such as drug screening, personalized medicine and launching the future of cell therapy using organoids. However, clinical translation of organoids into cell replacement therapies is halted due to (A) a few preclinical studies demonstrating their efficacy and (B) the lack of robust, reproducible, and scalable methods of production in compliance with current pharmaceutical standards. In this issue of Stem Cell Research & Therapy [ref], Dossena and collaborators present a validated bioprocess design for large-scale production of human pancreatic organoids from cadaveric tissue in accordance with current good manufacturing practice. The authors also propose a set of specifications of starting materials and critical quality attributes of final products that are of interest to other developments provided that this type of medicines are different than any other medicinal product due to their complex composition and living nature of the active ingredient. Although large-scale production of functional cells secreting insulin is still a challenge, the development of methods such as the one presented by Dossena and collaborators contributes to move toward clinical use of organoids in the treatment of type 1 diabetes and opens avenues for future clinical use of organoids in degenerative pathologies.
• dc.description.sponsorship Work in JV’s laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient no. RD16/0011/0028), awarded by Generalitat de Catalunya as Consolidated Research Group (ref. 2017-SGR-719). Project PI19/ 01788 is funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF) - A way to build Europe
• dc.format.mimetype application/pdf
• dc.identifier.citation Vives J, Batlle-Morera L. The challenge of developing human 3D organoids into medicines. Stem Cell Res Ther. 2020 Mar 4; 11(1): 72. DOI: 10.1186/s13287-020-1586-1
• dc.identifier.doi http://dx.doi.org/10.1186/s13287-020-1586-1
• dc.identifier.issn 1757-6512
• dc.identifier.uri http://hdl.handle.net/10230/44498
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof Stem Cell Research & Therapy. 2020 Mar 4;11(1):72
• dc.rights © 2020 by Joaquim Vives, Laura Batlle-Morera. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.other Organoids
• dc.subject.other Pàncrees
• dc.subject.other Medicina regenerativa
• dc.subject.other Enginyeria de teixits
• dc.title The challenge of developing human 3D organoids into medicines
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion